<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03775577</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00129787</org_study_id>
    <secondary_id>R01HL061912</secondary_id>
    <nct_id>NCT03775577</nct_id>
  </id_info>
  <brief_title>Exercise Intolerance in Heart Failure</brief_title>
  <official_title>Exercise Intolerance in Heart Failure: the Role of Altered Cardiac and Skeletal Muscle Energetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are studying whether metabolic abnormalities in cardiac and skeletal muscle&#xD;
      in patients with heart failure with preserved ejection fraction (HFpEF) are associated with&#xD;
      debilitating exercise intolerance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research is being done to better understand why patients with heart failure have&#xD;
      difficulty exercising and performing some activities of daily living. Heart muscle and&#xD;
      skeletal muscle (in the legs and arms) depend on normal metabolism (the conversion of foods&#xD;
      to chemical fuel) to function properly. Investigators will measure metabolites in the heart&#xD;
      and leg muscles, including the levels of high energy phosphates and lipids (fats) using&#xD;
      magnetic resonance (MR) techniques. High-energy phosphates serve as a source of energy, which&#xD;
      is used by the heart and skeletal muscle for contraction. Magnetic resonance uses magnetic&#xD;
      fields to measure the levels of these substances.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Skeletal muscle mitochondrial function</measure>
    <time_frame>Baseline</time_frame>
    <description>Maximal oxidative capacity of leg muscle measured by 31P Magnetic Resonance Spectroscopy (MRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal muscle energetic decline during exercise</measure>
    <time_frame>Baseline</time_frame>
    <description>Creatine phosphate rate of decline (umol/g/min) during plantar flexion exercise measured by 31P MRS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac muscle energetics</measure>
    <time_frame>Baseline</time_frame>
    <description>Cardiac muscle phosphocreatine (PCr)/ adenosine triphosphate (ATP) and creatine kinase(CK) flux (umol/g/s) measured by 31P MRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Six minute walk test</measure>
    <time_frame>Six months</time_frame>
    <description>Six minute walk distance (m)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary exercise testing (CPET)</measure>
    <time_frame>Six months</time_frame>
    <description>Peak whole-body oxygen consumption rate during exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical heart failure outcome as assessed by number of hospitalizations</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical heart failure outcome as assessed by time to cardiovascular death</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical heart failure outcome as assessed by overall mortality</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>HFpEF</arm_group_label>
    <description>Participants with Heart Failure with Preserved Ejection Fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFrEF</arm_group_label>
    <description>Participants with Heart Failure with Reduced Ejection Fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertensive Subjects</arm_group_label>
    <description>Participants with Hypertension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <description>Participants without heart failure and without commodities</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Specimens&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People with and without heart failure will be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of either gender who are greater than 21 years of age (no upper age limit),&#xD;
&#xD;
          -  Permission of patient's clinical attending physician,&#xD;
&#xD;
          -  Previous clinical diagnosis of HF with current New York Heart Association (NYHA) Class&#xD;
             II-III symptoms for at least 1 month,&#xD;
&#xD;
          -  Left ventricular ejection fraction (EF) &gt;50% by echocardiography, MRI, CT or x-ray or&#xD;
             nuclear ventriculography within prior 12 months,&#xD;
&#xD;
          -  Stable medical therapy for at least 30 days (no addition or removal or major (&gt;100%)&#xD;
             dose change of Renin-Angiotensin-Aldosterone System (RAAS) antagonists, beta-blockers,&#xD;
             or calcium channel blockers for hypertension).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to understand the risks, benefits, and alternatives of participation and give&#xD;
             meaningful consent,&#xD;
&#xD;
          -  Contraindications to MRI such as implanted metallic objects (pre-existing cardiac&#xD;
             pacemakers, cerebral clips) or indwelling metallic projectiles,&#xD;
&#xD;
          -  Significant valvular abnormalities,&#xD;
&#xD;
          -  Pregnant women (women of childbearing potential will undergo blood or urine pregnancy&#xD;
             testing),&#xD;
&#xD;
          -  History of clinical CAD or significant epicardial coronary disease (&gt;50% stenosis) in&#xD;
             major coronary artery by x-ray or CT angiography unless (a) the patient underwent&#xD;
             prior successful revascularization with percutaneous coronary angioplasty within the&#xD;
             prior three years and (b) there are no residual lesions of &gt;50% on the most recent&#xD;
             coronary angiographic study.&#xD;
&#xD;
          -  History of infiltrative cardiomyopathy or constrictive pericarditis,&#xD;
&#xD;
          -  Cor pulmonale,&#xD;
&#xD;
          -  Significant pulmonary disease,&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt;20ml/min,&#xD;
&#xD;
          -  Any condition other than HF which could limit the ability to perform a 6MW or&#xD;
             cardiopulmonary exercise test (CPET) test (e.g., critical peripheral vascular disease,&#xD;
             significant orthopedic or neurological conditions),&#xD;
&#xD;
          -  Any diseases other than HF which are likely to significantly alter the patient's&#xD;
             global perception of status or quality of life over a period of 6 months.&#xD;
&#xD;
          -  Significant peripheral vascular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert G Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Kauffman</last_name>
    <phone>443-287-3475</phone>
    <email>mkauffm7@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tricia Steinberg, RN, MSN</last_name>
    <phone>443-287-3469</phone>
    <email>asteinb3@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tricia Steinberg, MSN</last_name>
      <phone>443-287-3469</phone>
      <email>asteinb3@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2018</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure with Preserved Ejection Fraction</keyword>
  <keyword>HFpEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

